Updated Nov 13, 2022 09:34

Albumins And Albuminates Market in the United States

Market Overview
The U.S. albumins and albuminates market shrank markedly to $ in , with a decrease of -% against the previous year. This figure reflects the total revenues of producers and importers (excluding logistics costs, retail marketing costs, and retailers' margins, which will be included in the final consumer price). In general, consumption faced a deep contraction. As a result, consumption attained the peak level of $. From 2013 to , the growth of the market remained at a somewhat lower figure.

In value terms, albumins and albuminates production rose markedly to $ in . Overall, production, however, recorded a relatively flat trend pattern. The growth pace was the most rapid in 2008 with an increase of % against the previous year. Albumins and albuminates production peaked at $ in 2013; however, from 2014 to , production failed to regain momentum.


Consumption
For the sixth consecutive year, the United States recorded decline in consumption of albumins, albuminates and other derivatives (excluding egg albumin), which decreased by -% to tons in . Over the period under review, consumption continues to indicate a deep slump. Over the period under review, consumption hit record highs at tons in 2012; however, from 2013 to , consumption failed to regain momentum.

The revenue of the albumins and albuminates market in the United States dropped to $ in , reducing by -% against the previous year. This figure reflects the total revenues of producers and importers (excluding logistics costs, retail marketing costs, and retailers' margins, which will be included in the final consumer price). Overall, consumption continues to indicate a abrupt curtailment. As a result, consumption attained the peak level of $. From 2013 to , the growth of the market remained at a lower figure.


Market Forecast
Depressed by shrinking demand for albumins and albuminates in the United States, the market is expected to continue its downward consumption trend over the next eight years. The performance of the market is forecast to contract with an anticipated CAGR of -% for the period from to , which is projected to depress the market volume to tons by the end of .

In value terms, the market is forecast to contract with an anticipated CAGR of -% for the period from to , which is projected to bring the market value to $ (in nominal prices) by the end of .


Market Structure
In , the share of imports in total consumption accounted for % in value terms and % in physical terms. The share of imports decreased moderately (- percentage point) over the period under review.


Trade Balance
The United States remains a net exporter of albumins and albuminates; in physical and value terms, exports consistently exceeded imports from 2007 to . In , there was a significant trade surplus of tons, which was equal to $. This tangible trade surplus reflects the fact that the market remains buoyed by domestic production, and the industry is highly incorporated into the global market, which is likely to continue in the medium term.